RxDoctor Payments Data

Erika Garza, MD

Family Medicine · San Antonio, TXNPI 1881727840

Payments from drug & device makers

$575in general payments, 2019–2025

Across 25 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$139
  • Johnson & Johnson$103
  • Abbott$92
  • Amgen$50
  • Merck$39
  • AbbVie$31
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$139
Johnson & Johnson(2 entities)2$103
Abbott4$92
Amgen3$50
Merck2$39
AbbVie1$31
Davol Inc.1$26
Pfizer2$26
Exact Sciences1$22
AstraZeneca1$18
Nevro Corp.1$16
Dysis Medical, Inc.1$16

How this compares

$575 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$4,507
Medicare patients
23
Services billed
99

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide118$289,906
JardianceEmpagliflozin114$199,202
JanuviaSitagliptin Phosphate98$159,314
OzempicSemaglutide90$143,079
EliquisApixaban101$106,431
Bydureon BciseExenatide Microspheres41$99,042
MounjaroTirzepatide60$68,439
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$36,545
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$31,613
MyrbetriqMirabegron27$30,826
LinzessLinaclotide30$28,213
XareltoRivaroxaban17$27,505
FarxigaDapagliflozin Propanediol16$24,699
JanumetSitagliptin Phos/Metformin Hcl14$14,611
Lantus SolostarInsulin Glargine,hum.Rec.Anlog85$14,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$139$358,345178 claims
MerckJanuvia, Janumet$39$173,924112 claims
PfizerEliquis$26$106,431101 claims
AstraZenecaFarxiga, Symbicort$18$37,32756 claims
AbbVieLinzess$31$28,21330 claims
Johnson & JohnsonXarelto$103$27,50517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →